| Oct 1 |
RedHill Biopharma Secures Opaganib COVID-19 Patent
|
| Oct 1 |
RedHill and Medi-Cal Deal Maintains Talicia® Reimbursement Without Prior Authorization for 15 Million Californians
|
| Sep 30 |
RedHill Announces New U.S. Coronavirus Patent for Opaganib, Valid Through 2041
|
| Sep 9 |
RedHill's Talicia® Listed as First-Line Choice for H. pylori in New American College of Gastroenterology Guidelines
|
| Sep 5 |
RedHill Biopharma regains compliance with Nasdaq
|
| Sep 5 |
RedHill Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
|
| Aug 29 |
RedHill Biopharma Announces First Half 2024 Business Highlights
|
| Aug 21 |
Three Undiscovered Gems in the United States Market
|
| Aug 21 |
Talicia® Launched in the United Arab Emirates
|
| Aug 19 |
RedHill shares climb on results indicating potential use of opaganib for obesity-related disorders
|
